Program
piclidenoson
Also written as “CF101”, “Piclidenoson” and “CF101 2mg”.
Its studies are mostly in Psoriasis · Arthritis, Rheumatoid · Keratoconjunctivitis Sicca · Glaucoma · COVID-19, led by Can-Fite BioPharma.
Furthest: phase 3, since Nov 3, 201015 company-led studies, 2 open or runningNext primary completion: Aug 31, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Can-Fite BioPharma | 152 open or running | phase 3since Nov 3, 2010 | Jan 23, 2006 | Aug 31, 2027phase 2 · NCT07410455 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 23, 2006First study: phase 2 study in Arthritis, RheumatoidFirst studyNCT00280917 · 254 enrolled · United States, Bulgaria, Israel and more
- Jul 6, 2006Phase 2 study in Keratoconjunctivitis SiccaNCT00349466 · 80 enrolled · Israel
- Jan 29, 2007Phase 2 study in PsoriasisNCT00428974 · 76 enrolled · Israel
- Nov 8, 2007Phase 2 study in Arthritis, RheumatoidNCT00556894 · 253 enrolled · Bulgaria, Czechia, Israel and more
- Feb 3, 2009Phase 2 study in Osteoarthritis, KneeNCT00837291 · Israel
- Dec 15, 20092 phase 2 studiesNCT01033422, NCT01034306
- Nov 3, 2010Phase 3 study in Keratoconjunctivitis SiccaNCT01235234 · 236 enrolled · Israel
- Dec 9, 2010Phase 3 study in PsoriasisNCT01265667 · 293 enrolled · United States, Bulgaria, Israel and more
- Jul 14, 2013Phase 2 study in Uveitis, PosteriorNCT01905124 · Israel
- Dec 16, 2015Phase 3 study in Arthritis, RheumatoidNCT02647762 · 244 enrolled · Bosnia and Herzegovina, Canada, Israel and more
- May 24, 2017Phase 3 study in Plaque PsoriasisNCT03168256 · 528 enrolled · Bosnia and Herzegovina, Bulgaria, Canada and more
- Apr 1, 2020Phase 2 study in COVID-19NCT04333472 · 6 enrolled · Bulgaria, Israel, Romania
- Oct 9, 2024Phase 3 study in PsoriasisNCT06643260 · 705 planned
- Feb 8, 2026Phase 2 study in Oculocerebrorenal SyndromeNCT07410455 · 5 planned · Italy
Ahead
- Aug 31, 2027Primary completion: phase 2 study in Oculocerebrorenal SyndromeNCT07410455
- Dec 2027Primary completion: phase 3 study in PsoriasisNCT06643260
TargetBeta
ADORA3 →read by rule
“An orally bioavailable, adenosine A3 receptor (A3AR) agonist ”NCIt, by rule
“Adenosine A3 receptor agonist”ChEMBL 37, by rule
Other programs on ADORA3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Caffeinerule | Boehringer Ingelheim | phase 4 | 30 |
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07410455Oculocerebrorenal Syndrome · Italy | 2 | Not yet recruiting | Aug 31, 2027 | 5 |
| NCT06643260Psoriasis | 3 | Not yet recruiting | Dec 2027 | 705 |
| NCT04333472COVID-19 · Bulgaria, Israel, Romania | 2 | Completed | Mar 6, 2022 | 6 |
| NCT03168256Plaque Psoriasis · Bosnia and Herzegovina, Bulgaria, Canada and more | 3 | Completed | Jan 6, 2022 | 528 |
| NCT02647762Arthritis, Rheumatoid · Bosnia and Herzegovina, Canada, Israel and more | 3 | Terminated | Nov 30, 2020 | 244 |
| NCT01905124Uveitis, Posterior · Israel | 2 | Withdrawn | Sep 2019 | 0 |
| NCT01265667Psoriasis · United States, Bulgaria, Israel and more | 3 | Completed | Mar 2015 | 293 |
| NCT01235234Keratoconjunctivitis Sicca · Israel | 3 | Completed | Nov 2013 | 236 |
| NCT01034306Arthritis, Rheumatoid · Bulgaria, Israel | 2 | Completed | Dec 2013 | 79 |
| NCT01033422Ocular Hypertension · Bulgaria, Israel | 2 | Completed | Dec 2016 | 89 |
| NCT00837291Osteoarthritis, Knee · Israel | 2 | Withdrawn | Dec 2018 | 0 |
| NCT00556894Arthritis, Rheumatoid · Bulgaria, Czechia, Israel and more | 2 | Completed | Mar 2009 | 253 |
| NCT00428974Psoriasis · Israel | 2 | Completed | Sep 2009 | 76 |
| NCT00349466Keratoconjunctivitis Sicca · Israel | 2 | Completed | May 2009 | 80 |
| NCT00280917Arthritis, Rheumatoid · United States, Bulgaria, Israel and more | 2 | Completed | Apr 2007 | 254 |
How it is read
Names in the registry
- “CF101”, 9 entries
- “Piclidenoson”, 2 entries
- “CF101 2mg”, 2 entries
- “piclidenoson”, 1 entry
- “CF101 1mg”, 1 entry
Conditions, from the studies’ own filings
- Psoriasis, 4 studies
- Arthritis, Rheumatoid, 4 studies
- Keratoconjunctivitis Sicca, 2 studies
- Glaucoma, 1 study
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.